Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $27.7500 (3.08%) ($26.6400 - $28.3000) on Wed. Jul. 22, 2015. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.56% (three month average) | RSI | 59 | Latest Price | $27.7500(3.08%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.9% a day on average for past five trading days. | Weekly Trend | ADMS advances 2.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(34%) IBB(32%) IWM(22%) XOP(21%) XLV(20%) | Factors Impacting ADMS price | ADMS will decline at least -1.78% in a week (0% probabilities). VIXM(-15%) BNDX(-10%) TLT(-7%) SHY(-7%) UUP(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.78% (StdDev 3.56%) | Hourly BBV | 0 () | Intraday Trend | 4% | | | |
|
5 Day Moving Average | $28.04(-1.03%) | 10 Day Moving Average | $28.06(-1.1%) | 20 Day Moving Average | $27.35(1.46%) | To recent high | -6.9% | To recent low | 64.3% | Market Cap | $785m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |